Nutzen und Risiken der Immunsuppression bei chronisch entzündlichen Darmerkrankungen

Schlüsselwörter

Immunsuppression - chronisch entzündliche Darmerkrankungen - Morbus Crohn

Key words

immunosuppression - inflammatory bowel disease - Crohn’s disease

Literatur

• 1 FDA Board Document. Update on the TNF-alpha blocking agents; [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm]. 2003
• 2 Akobeng A K, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease. Cochrane Database Syst Rev 2005 CD003715
• 3 Akobeng A K, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2004 CD003574
• 4 Caprilli R, Viscido A, Latella G. Current management of severe ulcerative colitis.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 92-101
• 5 Cohen R D, Woseth D M, Thisted R A, Hanauer S B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.  Am J Gastroenterol. 2000;  95 1263-1276
• 6 Colombel J F, Ferrari N. et al . Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy.  Gastroenterology. 2000;  118 1025-1030
• 7 Colombel J F, Loftus Jr E V, Tremaine W J. et al . The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients.  Gastroenterology. 2004;  126 19-31
• 8 Cosnes J. et al . Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery.  Gut. 2005;  54 237-241
• 9 Dayharsh G A, Loftus Jr E V, Sandborn W J. et al . Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.  Gastroenterology. 2002;  122 72-77
• 10 Feagan B G. Maintenance therapy for inflammatory bowel disease.  Am J Gastroenterol. 2003;  98 S6-S17
• 11 Feagan B G, Rochon J, Fedorak R N. et al . Methotrexate for the treatment of Crohn’s disease.  N Engl J Med. 1995;  332 292-297
• 12 Fernandez-Banares F, Bertran X. et al . Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis.  Am J Gastroenterol. 1996;  91 2498-2499
• 13 Hanauer S B. Immunogenicity of infliximab in Crohn’s disease.  N Engl J Med. 2003;  348 2155-2156 , ; author reply 2155 – 2156
• 14 Hanauer S B, Sandborn W J, Rutgeerts P. et al . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial.  Gastroenterology. 2006;  130 323-333; quiz 591
• 15 Jarnerot G, Hertervig E. et al . Infliximab as rescue therapy in severe to moderately severe ulcerative colitis.  Gastroenterology. 2005;  128 1805-1811
• 16 Kamm M A. Chronic active disease and maintaining remission in Crohn’s disease.  Aliment Pharmacol Ther. 2004;  20 Suppl 4 102-105
• 17 Kandiel A E, Fraser A J, Korelitz B I, Brensinger C M, Lewis J D. Azathioprine and 6-mercaptopurine use for inflammatory bowel disease is associated with an increased risk of lymphoma.  Gastroenterology. 2004;  126 19-26
• 18 Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies.  J Clin Gastroenterol. 2005;  39 557-569
• 19 Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment.  Scand J Gastroenterol. 1993;  28 821-826
• 20 Kozarek R A. Long-term treatment of Crohn’s disease with methotrexate, or, why’s a nice drug like you still a wannabe in the treatment of inflammatory bowel disease?.  Am J Gastroenterol. 2000;  95 1619-1620
• 21 Kremer J M, Alarcon G S, Lightfoot Jr R W. et al . Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.  Arthritis Rheum. 1994;  37 316-328
• 22 Kwon H J, Farrell R J. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.  Crit Rev Oncol Hematol. 2005;  56 169-178
• 23 Lemann M, Mary J Y, Colombel J F. et al . A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine.  Gastroenterology. 2005;  128 1812-1818
• 24 Lemann M, Zenjari T, Bouhnik Y. et al . Methotrexate in Crohn’s disease: long-term efficacy and toxicity.  Am J Gastroenterol. 2000;  95 1730-1734
• 25 Lewis J D. How safe is immunomodulator therapy?.  Inflamm Bowel Dis. 2001;  7 178-179
• 26 Lewis J D, Bilker W B. et al . Inflammatory bowel disease is not associated with an increased risk of lymphoma.  Gastroenterology. 2001;  121 1080-1087
• 27 Lichtenstein G R, Feagan B G, Cohen R D. et al . Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry.  Clin Gastroenterol Hepatol. 2006;  4 621-630
• 28 Lichtiger S, Present D H, Kornbluth A. et al . Cyclosporine in severe ulcerative colitis refractory to steroid therapy.  N Engl J Med. 1994;  330 1841-1845
• 29 Orchard T, Probert C S, Keshav S. Maintenance therapy in patients with ulcerative colitis.  Aliment Pharmacol Ther. 2006;  24 Suppl 1 17-22
• 30 Roenigk Jr H H, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference.  Journal of the American Academy of Dermatology. 1998;  38 478-485
• 31 Rutgeerts P. Current dilemmas in the management of inflammatory bowel disease.  Eur J Surg . 2002;  Suppl 58-61
• 32 Rutgeerts P, Diamond R H, Bala M. et al . Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease.  Gastrointest Endosc. 2006;  63 433-442; quiz 464
• 33 Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease.  Gastroenterology. 2004;  126 1593-1610
• 34 Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease--seven years on.  Aliment Pharmacol Ther. 2006;  23 451-463
• 35 Rutgeerts P J. Efficacy of infliximab in Crohn’s disease – induction and maintenance of remission.  Aliment Pharmacol Ther. 1999;  13 Suppl 4 9-15; discussion 38
• 36 Safdi M, DeMicco M, Sninsky C. et al . A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.  Am J Gastroenterol. 1997;  92 1867-1871
• 37 Sands B E, Anderson F H, Bernstein C N. et al . Infliximab maintenance therapy for fistulizing Crohn’s disease.  N Engl J Med. 2004;  350 876-885
• 38 Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions.  Am J Gastroenterol. 2003;  98 530-537
• 39 Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005 CD004277
• 40 Siegel C A, Sands B E. Practical management of inflammatory bowel disease patients taking immunomodulators.  Aliment Pharmacol Ther. 2005;  22 1-16
• 41 Sohi S, Cohen R D. Management of refractory ulcerative colitis.  Curr Treat Options Gastroenterol. 2006;  9 234-245
• 42 Srinivasan R, Lewis J D. Malignancies in inflammatory bowel disease.  Curr Opin Gastroenterol. 2003;  19 366-370
• 43 Sutherland L, Macdonald J K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 CD000544
• 44 Te H S, Schiano T D, Kuan S F. et al . Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease.  Am J Gastroenterol. 2000;  95 3150-3156
• 45 Timmer A, McDonald J, Macdonald J. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 CD000478
• 46 Travis S P, Stange E F. et al . European evidence based consensus on the diagnosis and management of Crohn’s disease.  Gut. 2006;  55 Suppl 1 i16-35
• 47 Truelove S C, Witts L J. Cortisone in ulcerative colitis; final report on a therapeutic trial.  Br Med J. 1955;  2 1041-1048
• 48 Van Assche G, D’Haens G, Noman M. et al . Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.  Gastroenterology. 2003;  125 1025-1031
• 49 Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases.  Curr Opin Gastroenterol. 2005;  21 443-447
• 50 Vilien M, Dahlerup J F. et al . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increased relapse rate the following year.  Aliment Pharmacol Ther. 2004;  19 1147-1152